
DAVA Oncology
@DAVAOnc
DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
You might like
Virtual registration for the 8th DAVA Summit on Genitourinary Malignancies is now open! ✨Register now and don't miss this incredible opportunity to learn, connect, and be inspired. forms.office.com/r/DtH8RJh47a #DAVAGU

Announcing the 8th Summit on Genitourinary Malignancies by DAVA Oncology! Join us this November to explore the latest data and emerging strategies in bladder, kidney & prostate cancer. Keep your 👀 on our socials for a sneak peek. Check out the website! dava.link/BermudaGU25

@DAVAOnc Academia without friends at meetings is like Bermuda without sunshine Why would you want it? 🌞 Grateful for all I’ve learned from these friends. #DAVAGI




Day 3 of @DAVAOnc GI malignancies summit is in the books. Had to snap a pic with the maestro @vinaykjain17 who makes this and many other great events happen in the oncology space! #livertwitter

Nice to see friends, mentors and industry partners to embark on more trials in PDAC. @utswcancer
Can HDAC inhibitors expand treatment options in PDAC? Early data: ivaltinostat + chemo (ORR 25%, mOS 11.7 mo) and entinostat + IO (ORR 11%). Discussed by @Salthecancerguy @UTSW #DAVAGI




Delighted to be back in Bermuda 🏝️ for @DAVAOnc GI Malignancies Global Summit - sharing updates on new vaccine and immuno-oncology strategies for patients with colorectal and pancreatic cancer 🌍🎗️🧬


Excited to have these trials available for our patients! @AdventHealthCFL @drzakoncology
ACTION & RESTORE trials take exercise beyond survivorship, testing whether aerobic training during adjuvant therapy influences both clinical outcomes & biological remodeling in colon cancer. @Dr_M_Tejani @AdventHealthCFL #DAVAGI




Mayo Clinic, MD Anderson, Stanford and U Miami representing NETs at #DavaOnc Day 3 of 4 done!! @DAVAOnc

Ending @DAVAOnc GI malignancies on a high note with a session on liver metastases and locally advanced #HCC moderated by @docamitgs @sepideh_gholami #livertwitter

The very last @DAVAOnc summit on GI malignancies is underway. Congratulations to @vinaykjain17 and the DAVA team for another tour de force. Over 170 talks in 4 days. Lots of fruitful interactions and learning! #DAVAGI

The 2025 DAVA Bermuda GI Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVAGI




Gastric cancer with peritoneal metastases (20–45% cases; OS 3–4 mountreated) remains difficult to treat. @Jenny_J_Li @MDAndersonNews reviewed IP chemo approaches (HIPEC, NIPEC, PIPAC); early trials show promise but remain investigational. #DAVAGI




Starting Now: Peritoneal Mets and Appendiceal Cancer Moderated by: @vinaykjain17 #DAVAGI

EpCAM is overexpressed in GI cancers. Dr. Andrew Coveler @FredHutch highlighted KK-2269 & BA3182. KK-2269 (EpCAM–CD40) showed preclinical synergy w/ docetaxel; trials ongoing. BA3182 (EpCAM–CD3 CAB, n=39) showed manageable safety & favorable SC PK vs IV. #DAVAGI




Starting Now: Antibody-drug Conjugates Moderated by: @kanwal_raghav @MDAndersonnews #DAVAGI

CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.




At #DAVAGI, @rutikamehtaMD presented utility of ctDNA MRD testing in gastric/upper GI cancers: persistence/rise predicts recurrence. ctDNA detects recurrence upto 3.5 mo before imaging. In surveillance, positivity→81% recurrence, mRFS 6 mo; negativity→13.5% recurrence, NR mRFS.



Starting Now: Emerging Approaches to Increase IO Efficacy in GE Junction Tumors Moderated by: Dr. Manish Shah @WeillCornell #DAVAGI

Cancer-driven vagal hyperactivation may contribute to cachexia. Dr. @drsmags (@MDAndersonNews) discusses vagal blockade, which reduced cachexia and improved survival in PDAC models. Trials are planned to test QOL outcomes. #DAVAGI



In Locally Advanced Pancreatic Cancer (LAPC), PANOVA-3 showed TTF + gem-nab-pacimproved mOS and pain-free survival, though PFS and ORR were similar. Dr. @MPishvaian (@hopkinskimmel) notes device was well tolerated; biomarker work ongoing. #DAVAGI



United States Trends
- 1. Inside the NBA 3,485 posts
- 2. East Wing 151K posts
- 3. Wirtz 62K posts
- 4. Hamburger Helper 1,753 posts
- 5. $TSLA 47.8K posts
- 6. Elander 3,634 posts
- 7. Shaq 8,869 posts
- 8. Rosneft 5,810 posts
- 9. SNAP 658K posts
- 10. 5sos 5,461 posts
- 11. Talus 16.4K posts
- 12. Estevao 54.4K posts
- 13. Danny White 3,120 posts
- 14. #YesOnProp50 10.1K posts
- 15. Goodell 4,612 posts
- 16. Surviving Mormonism N/A
- 17. Charles Barkley N/A
- 18. Atalanta 18.1K posts
- 19. Ajax 83.9K posts
- 20. Tony Vitello 13.2K posts
You might like
-
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein -
Krina Patel
@DrKrinaPatel -
SWOG Cancer Research Network
@SWOG -
Suresh S. Ramalingam, MD, FASCO
@RamalingamMD -
Eric J. Small, MD, FASCO
@ASCOPres -
Jason Westin, MD FACP FASCO
@Lymphoma_Doc -
iwCLL
@iwCLL -
Vishal Navani, MD
@navstruck -
Julie Vose
@DrJulieVose -
Tycel Phillips
@LymphClinician -
Ticiana Batista (Leal)
@LealTiciana -
Binay Shah, MD, MHA
@binayshah -
Danilov Lab
@DanilovLab -
Andrew M. Evens, DO, MBA, MSc
@DrAEvens -
Skip Burris, MD
@BurrisSkip
Something went wrong.
Something went wrong.